These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 10470192

  • 1. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P, Seidel D.
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N, Ragab HM, El Maksoud NA, Shaalan M.
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [Abstract] [Full Text] [Related]

  • 3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [Abstract] [Full Text] [Related]

  • 4. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farrus B, Ballesta AM.
    Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
    [Abstract] [Full Text] [Related]

  • 5. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farrus B, Ballesta AM.
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [Abstract] [Full Text] [Related]

  • 6. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T, Schürenkämper P, Minguillon C, Lichtenegger W.
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
    Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A.
    Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
    [Abstract] [Full Text] [Related]

  • 8. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M.
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D'Amico DF.
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [Abstract] [Full Text] [Related]

  • 10. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer.
    Lumachi F, Basso SM, Bonamini M, Marzano B, Milan E, Waclaw BU, Chiara GB.
    Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
    Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P.
    Anticancer Res; 2000 Jun; 20(6C):4751-5. PubMed ID: 11205212
    [Abstract] [Full Text] [Related]

  • 12. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC, Day W, Jones B, Loo WT, Chow LW.
    Anticancer Res; 2002 Jun; 22(3):1865-8. PubMed ID: 12168883
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L, Castoldi R, Di Palo S, Arru M, Stella M, Orsenigo E, Gavazzi F, Ferla G, Di Carlo V, Staudacher C.
    Chir Ital; 2005 Jun; 57(5):555-70. PubMed ID: 16241086
    [Abstract] [Full Text] [Related]

  • 14. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR, Lee WJ, Huang MT, Lin HH.
    Hepatogastroenterology; 2002 Jun; 49(46):1157-60. PubMed ID: 12143226
    [Abstract] [Full Text] [Related]

  • 15. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M, Kataja V, Hämäläinen E, Kosma VM, Penttilä I, Alhava E.
    Anticancer Res; 1997 Jun; 17(2B):1231-4. PubMed ID: 9137478
    [Abstract] [Full Text] [Related]

  • 16. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P, Miccoli P.
    BMC Cancer; 2006 Nov 20; 6():269. PubMed ID: 17116247
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M, Bussen S, Trott S, Caffier H.
    Anticancer Res; 1999 Nov 20; 19(4A):2567-70. PubMed ID: 10470196
    [Abstract] [Full Text] [Related]

  • 18. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM, Trangas T.
    Cancer Res; 2000 Oct 01; 60(19):5427-33. PubMed ID: 11034084
    [Abstract] [Full Text] [Related]

  • 19. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di Filippo F, Cognetti F, Botti C, Roselli M.
    Clin Cancer Res; 2001 Aug 01; 7(8):2357-62. PubMed ID: 11489813
    [Abstract] [Full Text] [Related]

  • 20. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R, Albrecht S, Richter B, Deutschmann K, Zimmermann T, Distler W.
    Luminescence; 2000 Aug 01; 15(5):283-9. PubMed ID: 11038485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.